1. |
Donepezil study underpowered, say Eisai and Pfizer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
HIV drug price drops, UNAIDS calls for more funds |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
Fondaparinux cost saving over enoxaparin for VTE prophylaxis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Almost all physicians in Finland are against complete direct-to-consumer (DTC) advertising of prescription drugs, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
Bone marrow cell transfer BOOSTs LVEF after MI? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Temozolomide for brain metastases? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
Treatment of ACS: enoxaparin or heparin? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
CARDS: atorvastatin reduces risk of cardiovascular events in diabetes |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 9-10
Williamson David,
Preview
|
|
摘要:
Coronary heart disease (CHD) is the leading cause of mortality in patients with type 2 diabetes mellitus, in whom the absolute risk of CHD, for any given level of serum cholesterol, is estimated to be approximately three times greater than for adults without diabetes. Against this background, the results of the Collaborative AtoRvastatin Diabetes Study (CARDS), presented recently at the 64th Annual Scientific Sessions of the American Diabetes Association [Orlando, US; June, 2004], show that lipid-lowering therapy is effective for the primary prevention of cardiovascular events in diabetic patients with no prior history of myocardial infarction (MI) or stroke. Patients with type 2 diabetes who were treated with atorvastatin [Lipitor] at a daily dose of 10mg had a 37% reduction in the risk of major cardiovascular events and a 48% reduction in the incidence of stroke, compared with patients who received placebo; overall mortality in atorvastatin-treated patients was also reduced, by 27%. Moreover, these benefits extended to patients whose LDL-cholesterol levels were already relatively low prior to commencing treatment with atorvastatin, suggesting that statin therapy may be of significant benefit to the majority of patients with diabetes.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
Statins reduce risk of cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
Fluconazole superior to itraconazole in oropharyngeal candidiasis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1446,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|